The Latest Breaking News from Kenvue

Quitting smoking can be extremely difficult, but there are lots of treatments options out there to help.

Kenvue is all set to announce its second-quarter results this month, and analysts forecast a single-digit decline in the company’s bottom-line figure.

While Kenvue's shares have notably lagged behind the Dow Jones in the past year, analysts hold a moderately bullish outlook on the stock.

When the market pulls back, it's an opportunity to invest in high-yield dividend stocks like Kenvue, Enterprise Products Partners, and Verizon, which offer attractive yields and growth potential.

Despite Kenvue lagging behind the broader market, Wall Street analysts remain optimistic about the stock’s prospects.

Asian shares have mostly advanced after Wall Street ticked higher amid hopes that Japan's moves to keep interest rates easy for investors could augur similar trends in the rest of the world

Johnson & Johnson's newly-structured business, which no longer includes a consumer healthcare unit, is seeing solid demand for its new cancer-focused treatments Carvykti and Tecvayli.

With an aging population worldwide, the growing prevalence of chronic diseases, new drug discoveries and rapid digital advancements, the outlook for the pharmaceutical sector remains optimistic. Pharma stocks Johnson & Johnson (JNJ) and Madrigal Pharmaceuticals (MDGL) will likely benefit from the industry’s bright prospects. But which of these stocks is…

This week’s episode of Fortune‘s Leadership Next podcast features conversations from the Fortune CEO Initiative conference.

J&J CEO Joaquin Duato's interview on Baby Powder cancer lawsuits, Kenvue, and the COVID vaccine.

Johnson & Johnson stock (JNJ) recently spun off its consumer Kenvue business, which trades separately under the symbol KVUE. However, JNJ stock has dipped and now looks like good value.